Biotechnology

Labstat Inc. and Universal/Global Laboratory Services (GLS) Enter Partnership to Boost Testing Solutions for Tobacco/Nicotine Industry

by

Enhanced Analytical Capabilities Offer Comprehensive, Customer-Centric Solutions KITCHENER, ON, Aug. 29, 2023 /PRNewswire/ — Labstat Inc., A Certified Group Company, has entered a strategic partnership with Global Laboratory Services, Inc. (GLS), a subsidiary of Universal Leaf Tobacco Company, Inc. This alliance aligns Labstat’s cutting-edge capabilities with GLS’s comprehensive testing services, enabling both companies to offer tobacco … Read more

PhenomeX to Report Second Quarter 2023 Financial Results on August 14, 2023

by

EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ — PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023. About PhenomeX Inc. PhenomeX is empowering scientists to leverage the full potential of each cell and drive the … Read more

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

by

HONG KONG, Germantown, Md. and SUZHOU, China, July 27, 2023  /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the … Read more

Amprion’s αSynuclein Seed Amplification Assay to be Showcased at Alzheimer’s Association International Conference® 2023 (AAIC®)

by

Two posters at AAIC will feature SYNTap®, the only seed amplification assay available to aid the diagnosis of synucleinopathies SAN DIEGO, July 15, 2023 /PRNewswire/ — Amprion, a global leader in the advancement of neurodegenerative disorder diagnosis, will be in attendance at the Alzheimer’s Association International Conference® 2023 (AAIC®) in Amsterdam on July 16-20. AAIC … Read more

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

by

LUND, Sweden, July 12, 2023 /PRNewswire/ — Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the … Read more

CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine

by

Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells PLEASANTON, Calif., July 5, 2023 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its single-cell genomic technologies were used in a study published in the journal Nature Medicine about new gene signatures that explain why some … Read more

FDA Roundup: June 16, 2023

by

SILVER SPRING, Md., June 16, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA posted information on its website regarding the formula for COVID-19 vaccines for the 2023-2024 fall and winter seasons. The FDA has advised manufacturers seeking to update … Read more

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

by

HEFEI, China, June 16, 2023 /PRNewswire/ — TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling … Read more

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

by

NANJING, China, June 16, 2023 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs” or “Company”) today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other malignant tumors, has been approved by the FDA (U.S. Food and Drug Administration). At … Read more

NABR reicht Petition zur Anfechtung der Aufnahme des Langschwanzmakaken (Long-Tailed Macaque) in die Liste der IUCN ein

by

WASHINGTON, 16. Juni 2023 /PRNewswire/ — In Zusammenarbeit mit anerkannten, unabhängigen Wissenschaftlern reichte die National Association for Biomedical Research (NABR) heute eine Petition bei der International Union for Conservation of Nature (IUCN) ein, in der sie die jüngste Einstufung des Langschwanzmakaken (Cynomolgus macaque) nach den Kriterien der IUCN als gefährdet anzweifelt. Diese Einstufung ist das … Read more